Genomics England names QIAGEN Bioinformatics one of the UK100K project assessment winners
Oct 14 2014

Genomics England names QIAGEN Bioinformatics one of the UK100K project assessment winners

  • Ambitious project to sequence and interpret 100,000 whole genomes from NHS patients in the United Kingdom names key technology collaborators

  • QIAGEN Bioinformatics to provide project researchers access to Ingenuity® Variant Analysis™ to enable the rapid identification of disease causal variants from NGS data 

  • Focus on patients with cancer and rare diseases


Redwood City, Calif., October 13, 2014 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced today that its business area, QIAGEN Bioinformatics, has been named by Genomics England (GeL) an assessment winner for the UK100K project, along with other life science technology providers. The company will be providing project researchers access to Ingenuity® Variant Analysis™, a powerful web-application that allows users to rapidly identify and prioritize disease causing genetic variants using advanced analytics powered by published biological evidence and large numbers of sequenced genomes. 

“Unlocking the full value of genomic data requires collaborations that bring together the best technology and minds from government, academic and commercial organizations,” said Laura Furmanski, QIAGEN Senior Vice President and Head of the Bioinformatics Business Area. “The UK100K project is a shining example of what is possible when many great institutions and technology innovators combine forces to advance the vision of personalized medicine. QIAGEN is honored to have been selected as an assessment winner and we look forward to working with the entire GeL team to demonstrate how linking rich sets of patient data with genomic information can power new ways of treating and caring for people fighting cancer and rare diseases.”

Genomics England was set up by the UK Department of Health to deliver this flagship project that will sequence 100,000 whole genomes from NHS patients by 2017. Its four main aims are; to create an ethical and transparent program based on consent; to bring benefit to patients and set up a genomic medicine service for the NHS; to enable new scientific discovery and medical insights; and to kick start the development of a UK genomics industry. The first samples for sequencing are being taken from patients living in England and may also include patient data from residents of Scotland, Wales and Northern Ireland. More details can be found at http://www.genomicsengland.co.uk/

QIAGEN offers industry-leading applications for the analysis, interpretation, and reporting of biological data though an industry leading portfolio of products that include the Ingenuity, CLC bio and BIOBASE product lines. The analysis, interpretation and reporting of sequencing data are some of the most significant challenges in modern molecular methods.  For interpretation, data must be examined within the context of complex biological processes, and rapidly increasing throughput can make the interpretation without advanced, effective tools very time and labor intensive.  QIAGEN’s portfolio of powerful tools addresses this bottleneck and other data analysis and interpretation challenges with innovative applications based on cutting-edge bioinformatics.

For more information, visit http://www.qiagen.com/products/bioinformatics.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of June 30, 2014, QIAGEN employed approximately 4,200 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

SOCIAL SHARING

Share this page